Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Trial Profile

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Planning
Phase of Trial: Phase II/III

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs DCR PHXC (Primary)
  • Indications Primary hyperoxaluria
  • Focus Adverse reactions; Registrational
  • Acronyms PHYOX 3
  • Sponsors Dicerna Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2018 New trial record
    • 08 Mar 2018 According to a Dicerna Pharmaceuticals media release, the company expects to initiate this trial in the first quarter of 2019, pending positive POC data and regulatory approvals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top